We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Francis
Drobniewski
f.drobniewski@imperial.ac.uk
Victor
Mariano
v.mariano13@imperial.ac.uk
Provisional assignment of new diseases of uncertain etiology
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe disease, coronavirus disease 2019 (COVID-19) in a subset of patients who require hospitalisation. This occurs more frequently in non-vaccinated or partly vaccinated persons. The protective effect of vaccination diminishes with time since inoculation, while a third vaccination has been shown to restore protective effects against infection and severe disease. Recent analyses indicated differential effects of vaccines depending on viral variants. However, there is still limited knowledge to what extent different viral variants or specific viral sequences influence severity of disease. Knowledge is also limited as to what extent immune responses to different vaccines and/or vaccine schedules influence the clinical outcome of the infection. In addition, the impact of different therapeutic interventions during hospitalisation on clinical outcome remains to be further evaluated, particularly in relation to the specific viral variants.
This single-site UK study is part of the international EuCARE – Hospitalised study, which aims to collect data retrospectively from hospitalised COVID-19 patients in several countries globally. Analyses of these data will inform the clinical course of hospitalised COVID-19 patients in relation to the viral variants of concern or specific viral sequences and the patients’ vaccination status, including the vaccines used and their vaccination schedule. This knowledge will provide recommendations towards optimising clinical management and treatment of COVID-19 taking consideration the viral variant and vaccines used. Data required for this study have already been collected through the ISARIC study from patients hospitalised in University Hospitals Dorset NHS Foundation Trust from September 2020 to May 2021.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patients hospitalised with COVID-19 that are: 1. Less than 18 years old 2. Covid-19 not confirmed by PCR 3. Patients admitted in University Hospitals Dorset NHS Foundation Trust outside of the study period
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by European Commission .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53103
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
